TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03424421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subscapular sling
Description: semitendinosus subscapular sling procedure
Study: NCT00694460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 1 mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 0.5 mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three 0.1mL doses of Rabies Vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two 0.1mL doses of Rabies vaccine and two JE vaccine
Description: Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Two doses of JE vaccine
Description: Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
Study: NCT02889081

Intervention type: OTHER
Intervention: maternal biological folate level
Description: supplementation status and serum level

Intervention type: OTHER
Intervention: maternal biological folate level
Description: supplementation status and serum level

Intervention type: OTHER
Intervention: maternal biological Vitamin D level
Description: supplementation status and serum level

Intervention type: OTHER
Intervention: maternal biological Vitamin D level
Description: supplementation status and serum level
Study: NCT01187238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
Study: NCT04285606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-led rehab with short immobilization
Description: Short immobilization followed by patient-led shoulder rehab
Study: NCT03843359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered.
Study: NCT01125358

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, twice daily for up to 7 weeks of treatment
Study: NCT03843359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3745417
Description: GSK3745417 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Dostarlimab will be administered.
Study: NCT01856257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte Globulin (Rabbit)
Description: The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
Study: NCT03970135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting for 24 hours or until hypoglycemia (blood glucose \< 3mmol/L) or symptoms of hypoglycemia
Study: NCT01856257

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte Globulin (Rabbit)
Description: The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
Study: NCT03781908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nitrate
Description: First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling Pleural Catheter
Description: First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture.
Study: NCT01856257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: Basiliximab will be administered in two doses of 20 mg each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
Study: NCT01044810

Intervention type: DRUG
Intervention: Efavirenz-based regimens
Description: Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.

Intervention type: DRUG
Intervention: Efavirenz-based regimens
Description: Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.

Intervention type: DRUG
Intervention: Efavirenz-based regimens
Description: Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
Study: NCT01856257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
Study: NCT01102972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reyataz + Norvir + Truvada
Description: atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reyataz + Epzicom
Description: atazanavir 400mg + abacavir 600mg/lamivudine 300mg
Study: NCT00850382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse).
Study: NCT01767116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study: NCT04289753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR clinical decision support nudges
Description: Clinical decision support nudges delivered within the EHR when conditions meet alert triggering criteria.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief clinician education
Description: Clinicians will be invited to view brief education material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief clinician education
Description: Clinicians will be invited to view brief education material.
Study: NCT02256475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Study: NCT03102476

Intervention type: DRUG
Group type: OTHER
Intervention: Humalog
Description: Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
Study: NCT04584567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycyclin
Description: daily (100mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: daily (100mg)
Study: NCT03801135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Haemocomplettan will be infused after plasma exchange procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: Fresh frozen plasma will be part of replacement fluid
Study: NCT04584567

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycyclin
Description: daily (100mg)
Study: NCT04364997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo
Description: Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.
Study: NCT00663793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 mcg/kg
Study: NCT04364997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule
Description: Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride Enteric-coated Capsule Placebo
Description: Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine Hydrochloride Enteric-coated Capsule
Description: Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.
Study: NCT00663793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.
Study: NCT01809626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03679260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: 20 grams total carbs/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate restricted diet
Description: 20 grams total carbs/day
Study: NCT00850382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (\>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours.
Study: NCT04035694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Aware Sexual Health - High School
Description: Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
Study: NCT01922635

Intervention type: OTHER
Group type: OTHER
Intervention: Valadation of the metrological properties of questionnaire of quality of life
Study: NCT04203888

Intervention type: OTHER
Group type: OTHER
Intervention: Swedish Massage
Description: 60-minute Swedish Massage delivered in-home by a licensed massage therapist, 2 times per week with at least 48-hours between massage interventions.

Intervention type: OTHER
Group type: OTHER
Intervention: Yoga
Description: 60-minute yoga session delivered in-home by a certified yoga instructor, 2 times per week with at least 48-hours between yoga interventions.Yoga sessions will be based on the yoga postures available in the appendix of the December 2005 Annals of Internal Medicine article, Comparing Yoga, Exercise, and a Self-Care Book for Chronic Low Back Pain (Sherman KJ et al., 2005).
Study: NCT03112096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]THK-5351
Description: Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
Study: NCT03679260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-restricted diet
Description: Subject follows normal diet
Study: NCT03679260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-restricted diet
Description: Subject follows normal diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone counseling with dietitian
Description: Weekly calls with dietitian
Study: NCT02316743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine supplementation
Description: T4 supplementation for heart failure patients with subclinical hypothyroidism.
Study: NCT02501655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phase 1 - jet nebulizer
Description: Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phase 2- mesh nebulizer
Description: Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
Study: NCT01984619

Intervention type: DEVICE
Intervention: Cryotherapy for the utilization of wrinkle reduction (iovera)
Study: NCT00663793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: 24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: 1 mg PO once daily \[day -2 to day 12) 14 days total
Study: NCT04302870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride Oral Solution
Description: Memantine hydrocholoride taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride oral solution
Description: Trazodone Hydrochloride taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral solution
Description: Placebo taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride Oral Solution
Description: Amantadine Hydrochloride taken once daily
Study: NCT04390776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
Study: NCT03679260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone counseling with dietitian
Description: Weekly calls with dietitian
Study: NCT03664024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
Study: NCT01792661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced MyChart
Description: Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
Study: NCT03664024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m\^2 infusion, standard of care, Q3W, IV
Study: NCT04390776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.
Study: NCT03664024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 75 mg/m\^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.